Objective:To identify the effects of acupuncture and moxibustion therapy by soothing liver and regulating mind on the quality of life among the elders with depression.Methods:This was a single-blind,randomized,control...Objective:To identify the effects of acupuncture and moxibustion therapy by soothing liver and regulating mind on the quality of life among the elders with depression.Methods:This was a single-blind,randomized,controlled trial of 75 elders with depression conducted in Guangdong Province,China,in January to December 2010.Eligible patients were randomly divided into three treatment groups.22 patients received acupuncture and moxibustion treatment of soothing liver and regulating mind[group A,in acupuncture procedure:Hegu(合谷L14),Taichong(太冲LR3),Baihui(百会GV20)and Yinting(印堂GV29)were selected,in moxibustion procedure,bilateral Geshu(膈俞BL17)and Danshu(胆俞BL19)were selected,the moxibustion cones was placed on the acupoints,five cones were given to each point.In intradermal needling procedure,Xinshu(心俞BL15),and Ganshu(肝俞BL18)were selected].28 patients received acupoint shallow puncturing treatment(group B,patients received the same acupoints as in the group A,with a 2-3 mm needling depth and no needle sensation was required.A shorter duration of moxibustion and only 1-2 mm of needle body was inserted into the points when intradermal needling).25 patients received non-acupoint shallow puncturing treatment(group C,patients received non-acupoint shallow puncturing at points 10 mm lateral to LI4 and LR3,10 mm left side of GV20 and GV29 in acupuncture procedure;10 mm lateral to BL17 and BL19 in moxibustion procedure;10 mm lateral to BL15 and BL18 in intradermal needling procedure,with the same manipulation method as that in the group B).In all three groups,the treatment was given twice a week for 12 weeks.The Short Form(36)Health Survey(SF36)and TCM Symptom Scale Score as clinical efficacy and quality of life were used to quantitatively assess patients'outcomes before and after treatment.Results:The TCM Symptom Scale scores showed significant differences between the group A and C,and between group B and C(both P<0.05),while there was no significant difference between group A and B(P>0.05).An ite展开更多
目的探讨渴络欣胶囊联合培哚普利治疗早期糖尿病肾病的临床疗效。方法选取2021年6月—2023年1月郑州大学第五附属医院收治的168例早期糖尿病肾病患者,按随机数字表法将患者分为对照组和治疗组,每组各84例。对照组晨服培哚普利叔丁胺片,4...目的探讨渴络欣胶囊联合培哚普利治疗早期糖尿病肾病的临床疗效。方法选取2021年6月—2023年1月郑州大学第五附属医院收治的168例早期糖尿病肾病患者,按随机数字表法将患者分为对照组和治疗组,每组各84例。对照组晨服培哚普利叔丁胺片,4 mg/d,1次/d。治疗组在对照组基础上口服渴络欣胶囊,4粒/次,3次/d。两组疗程12周。比较两组临床疗效,治疗前后中医症状积分、肾功能指标[24 h尿蛋白定量(24 h UP)等]、相关量表[肾脏病生活质量量表1.3(KDQOL-SF 1.3)、简式抑郁-焦虑-压力量表(DASS-21)]评分及血清血管生成抑制蛋白1(VASH-1)、高迁移率族蛋白B1(HMGB1)、CXC趋化因子配体10(CXCL10)水平。结果治疗后,治疗组总有效率是94.05%,显著高于对照组的84.52%(P<0.05)。治疗后,两组气短乏力积分、咽干口渴积分、肢体麻木积分、肢体麻木积分、腰膝酸软积分、畏寒肢冷积分均较治疗前显著降低(P<0.05);治疗后,治疗组中医症状积分低于对照组(P<0.05)。治疗后,两组血肌酐(Scr)、24 h UP、尿蛋白排泄率(UAER)低于同组治疗前(P<0.05);治疗后,治疗组肾功能指标改善优于对照组(P<0.05)。治疗后,两组KDQOL-SF 1.3评分均显著增高,而DASS-21评分均显著降低(P<0.05);治疗后,治疗组KDQOL-SF 1.3评分和DASS-21评分改善优于对照组(P<0.05)。治疗后,两组血清VASH-1、HMGB1、CXCL10水平均显著降低(P<0.05);治疗后,治疗组血清VASH-1、HMGB1、CXCL10水平低于对照组(P<0.05)。结论渴络欣胶囊联合培哚普利治疗早期糖尿病肾病具有良好的疗效,能有效缓解机体炎症反应、控制肾组织纤维化,在患者症状和负面情绪减轻、肾功能和生活质量改善方面获得更佳效果,值得临床推广应用。展开更多
基金Youth fund project of the Natural Science Foundation of China:81303041Class general financial grant from the China Postdoctoral Science Foundation:2012M511784+3 种基金Science foundation of the Outstanding Young Innovative Personnel of Department of Education Guangdong Province:2012LYM_0043Special research foundation of the New Teacher Category for the Doctoral Program of Higher School by National Ministry of Education:20124425120005Special financial grant from the China Postdoctoral Science Foundation:2013T60793Science Foundation of the Postdoctoral Researchers in Guangzhou University of Chinese Medicine from Guangdong Provincial Department of Human Resources and Social Security Fund:BBK429122K19
文摘Objective:To identify the effects of acupuncture and moxibustion therapy by soothing liver and regulating mind on the quality of life among the elders with depression.Methods:This was a single-blind,randomized,controlled trial of 75 elders with depression conducted in Guangdong Province,China,in January to December 2010.Eligible patients were randomly divided into three treatment groups.22 patients received acupuncture and moxibustion treatment of soothing liver and regulating mind[group A,in acupuncture procedure:Hegu(合谷L14),Taichong(太冲LR3),Baihui(百会GV20)and Yinting(印堂GV29)were selected,in moxibustion procedure,bilateral Geshu(膈俞BL17)and Danshu(胆俞BL19)were selected,the moxibustion cones was placed on the acupoints,five cones were given to each point.In intradermal needling procedure,Xinshu(心俞BL15),and Ganshu(肝俞BL18)were selected].28 patients received acupoint shallow puncturing treatment(group B,patients received the same acupoints as in the group A,with a 2-3 mm needling depth and no needle sensation was required.A shorter duration of moxibustion and only 1-2 mm of needle body was inserted into the points when intradermal needling).25 patients received non-acupoint shallow puncturing treatment(group C,patients received non-acupoint shallow puncturing at points 10 mm lateral to LI4 and LR3,10 mm left side of GV20 and GV29 in acupuncture procedure;10 mm lateral to BL17 and BL19 in moxibustion procedure;10 mm lateral to BL15 and BL18 in intradermal needling procedure,with the same manipulation method as that in the group B).In all three groups,the treatment was given twice a week for 12 weeks.The Short Form(36)Health Survey(SF36)and TCM Symptom Scale Score as clinical efficacy and quality of life were used to quantitatively assess patients'outcomes before and after treatment.Results:The TCM Symptom Scale scores showed significant differences between the group A and C,and between group B and C(both P<0.05),while there was no significant difference between group A and B(P>0.05).An ite
文摘目的探讨渴络欣胶囊联合培哚普利治疗早期糖尿病肾病的临床疗效。方法选取2021年6月—2023年1月郑州大学第五附属医院收治的168例早期糖尿病肾病患者,按随机数字表法将患者分为对照组和治疗组,每组各84例。对照组晨服培哚普利叔丁胺片,4 mg/d,1次/d。治疗组在对照组基础上口服渴络欣胶囊,4粒/次,3次/d。两组疗程12周。比较两组临床疗效,治疗前后中医症状积分、肾功能指标[24 h尿蛋白定量(24 h UP)等]、相关量表[肾脏病生活质量量表1.3(KDQOL-SF 1.3)、简式抑郁-焦虑-压力量表(DASS-21)]评分及血清血管生成抑制蛋白1(VASH-1)、高迁移率族蛋白B1(HMGB1)、CXC趋化因子配体10(CXCL10)水平。结果治疗后,治疗组总有效率是94.05%,显著高于对照组的84.52%(P<0.05)。治疗后,两组气短乏力积分、咽干口渴积分、肢体麻木积分、肢体麻木积分、腰膝酸软积分、畏寒肢冷积分均较治疗前显著降低(P<0.05);治疗后,治疗组中医症状积分低于对照组(P<0.05)。治疗后,两组血肌酐(Scr)、24 h UP、尿蛋白排泄率(UAER)低于同组治疗前(P<0.05);治疗后,治疗组肾功能指标改善优于对照组(P<0.05)。治疗后,两组KDQOL-SF 1.3评分均显著增高,而DASS-21评分均显著降低(P<0.05);治疗后,治疗组KDQOL-SF 1.3评分和DASS-21评分改善优于对照组(P<0.05)。治疗后,两组血清VASH-1、HMGB1、CXCL10水平均显著降低(P<0.05);治疗后,治疗组血清VASH-1、HMGB1、CXCL10水平低于对照组(P<0.05)。结论渴络欣胶囊联合培哚普利治疗早期糖尿病肾病具有良好的疗效,能有效缓解机体炎症反应、控制肾组织纤维化,在患者症状和负面情绪减轻、肾功能和生活质量改善方面获得更佳效果,值得临床推广应用。
